Abstract

A 77-year-old man with atrial fibrillation and a CHA2DS2Vasc score of 6 for hypertension, age, diabetes, and previous stroke is brought to the emergency department with decreased level of consciousness. He is anticoagulated with rivaroxaban (a direct oral factor Xa inhibitor [FXaI]) and received his last dose about 4 hours before presentation. Urgent computed tomography of the head shows intracerebral hemorrhage. Because of his previous stroke, the patient’s family is concerned about treating the bleed with pharmacological agents that may increase the risk of stroke. What are the risks of thrombosis and mortality related to the use of prothrombin complex concentrates (PCCs) and andexanet alfa for patients with direct oral FXaI-associated major bleeding?

References

References
1.
Piran
S
,
Khatib
R
,
Schulman
S
, et al
.
Management of direct factor Xa inhibitor-related major bleeding with prothrombin complex concentrate: a meta-analysis
.
Blood Adv
.
2019
;
3
(
2
):
158
-
167
.
2.
Higgins
JP
,
Green
S
, eds.
Cochrane Handbook for Systematic Reviews of Interventions
.
Chichester, United Kingdom
:
John Wiley & Sons Ltd
;
2008
.
3.
Majeed
A
,
Ågren
A
,
Holmström
M
, et al
.
Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study
.
Blood
.
2017
;
130
(
15
):
1706
-
1712
.
4.
Schenk
B
,
Goerke
S
,
Beer
R
,
Helbok
R
,
Fries
D
,
Bachler
M
.
Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial
.
Thromb J
.
2018
;
16
:
1
.
5.
Schulman
S
,
Gross
PL
,
Ritchie
B
, et al
;
Study Investigators
.
Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study
.
Thromb Haemost
.
2018
;
118
(
5
):
842
-
851
.
6.
Testa
S
,
Ageno
W
,
Antonucci
E
, et al
.
Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry
.
Intern Emerg Med
.
2018
;
13
(
7
):
1051
-
1058
.
7.
Allison
TA
,
Lin
PJ
,
Gass
JA
, et al
.
Evaluation of the use of low-dose 4-factor prothrombin complex concentrate in the reversal of direct oral anticoagulants in bleeding patients [published online ahead of print 24 September 2018]
.
J Intensive Care Med
.
doi:10.1177/0885066618800657
.
8.
Arachchillage
DRJ
,
Alavian
S
,
Griffin
J
, et al
.
Efficacy and safety of prothrombin complex concentrate in patients treated with rivaroxaban or apixaban compared to warfarin presenting with major bleeding
.
Br J Haematol
.
2019
;
184
(
5
):
808
-
816
.
9.
Berger
K
,
Santibañez
M
,
Lin
L
,
Lesch
CA
.
A low-dose 4F-PCC protocol for DOAC-associated intracranial hemorrhage [published online ahead of print 14 April 2019]
.
J Intensive Care Med
.
doi:10.1177/0885066619840992
.
10.
Dybdahl
D
,
Walliser
G
,
Chance Spalding
M
,
Pershing
M
,
Kincaid
M
.
Four-factor prothrombin complex concentrate for the reversal of factor Xa inhibitors for traumatic intracranial hemorrhage [published online ahead of print 9 January 2019]
.
Am J Emerg Med
.
doi:10.1016/j.ajem.2019.01.008
.
11.
Grandhi
R
,
Newman
WC
,
Zhang
X
, et al
.
Administration of 4-factor prothrombin complex concentrate as an antidote for intracranial bleeding in patients taking direct factor Xa inhibitors
.
World Neurosurg
.
2015
;
84
(
6
):
1956
-
1961
.
12.
Harrison
SK
,
Garrett
JS
,
Kohman
KN
,
Kline
JA
.
Comparison of outcomes in patients with intracranial hemorrhage on factor Xa inhibitors versus vitamin K antagonists treated with 4-factor prothrombin complex concentrate
.
Proc Bayl Univ Med Cent
.
2018
;
31
(
2
):
153
-
156
.
13.
Müller
M
,
Eastline
J
,
Nagler
M
,
Exadaktylos
AK
,
Sauter
TC
.
Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists
.
Scand J Trauma Resusc Emerg Med
.
2019
;
27
(
1
):
48
.
14.
Sheikh-Taha
M
.
Treatment of apixaban- and rivaroxaban-associated major bleeding using 4-factor prothrombin complex concentrate
.
Intern Emerg Med
.
2019
;
14
(
2
):
265
-
269
.
15.
Smith
MN
,
Deloney
L
,
Carter
C
,
Weant
KA
,
Eriksson
EA
.
Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study
.
J Thromb Thrombolysis
.
2019
;
48
(
2
):
250
-
255
.
16.
Schulman
S
,
Kearon
C
;
Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
.
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
.
J Thromb Haemost
.
2005
;
3
(
4
):
692
-
694
.
17.
Khorsand
N
,
Majeed
A
,
Sarode
R
,
Beyer-Westendorf
J
,
Schulman
S
,
Meijer
K
;
Subcommittee on Control of Anticoagulation
.
Assessment of effectiveness of major bleeding management: proposed definitions for effective hemostasis: communication from the SSC of the ISTH
.
J Thromb Haemost
.
2016
;
14
(
1
):
211
-
214
.
18.
Sarode
R
,
Milling
TJ
Jr
,
Refaai
MA
, et al
.
Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study
.
Circulation
.
2013
;
128
(
11
):
1234
-
1243
.
19.
Mao
G
,
King
L
,
Young
S
,
Kaplan
R
.
Factor eight inhibitor bypassing agent (FEIBA) for reversal of target-specific oral anticoagulants in life-threatening intracranial bleeding
.
J Emerg Med
.
2017
;
52
(
5
):
731
-
737
.
20.
Connolly
SJ
,
Crowther
M
,
Eikelboom
JW
, et al
;
ANNEXA-4 Investigators
.
Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors
.
N Engl J Med
.
2019
;
380
(
14
):
1326
-
1335
.
21.
Dentali
F
,
Marchesi
C
,
Giorgi Pierfranceschi
M
, et al
.
Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists: a meta-analysis
.
Thromb Haemost
.
2011
;
106
(
3
):
429
-
438
.
You do not currently have access to this content.